The current status of Helicobacter pylori vaccines: A review

Helicobacter

Volumn 12, Issue 2, 2007, Pages 89-102

  Kabir, Shahjahan ^a  

^a Academic Research and Information Management   (Sweden)

Author keywords

Gastric cancer; Helicobacter pylori; Human challenge model; Peptic ulcer; Vaccines

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; BACTERIAL ANTIGEN; BACTERIUM LYSATE; CAGA PROTEIN; CHOLERA TOXIN; CHOLESTEROL; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; HELICOBACTER PYLORI ANTIGEN; HELICOBACTER PYLORI GHOST; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INTERLEUKIN 8; LIVE VACCINE; MURAMYL DIPEPTIDE; PLASMID DNA; RECOMBINANT ENZYME; RECOMBINANT UREASE; RECOMBINANT VACCINE; TRANSCRIPTOME; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACUOLATING TOXIN; VIRULENCE FACTOR; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BIOLOGICAL MODEL; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DOG; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXPERIMENTAL INFECTION; FEASIBILITY STUDY; FEVER; GENE VECTOR; GERBIL; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST; HUMAN; IMMUNOPROPHYLAXIS; LYMPHOCYTE FUNCTION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PASSIVE IMMUNIZATION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEOMICS; REGULATORY T LYMPHOCYTE; REPLICON; REVIEW; SHUTTLE VECTOR; SYSTEMIC THERAPY; T LYMPHOCYTE; TRANSCRIPTOMICS; TREATMENT DURATION; VACCINATION; VOMITING; WHOLE CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; POLIOVIRUS; SALMONELLA; T-LYMPHOCYTES; UREASE; VACCINES, DNA; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HELICOBACTER PYLORI; MASTIGOPHORA (FLAGELLATES); MUS; NEGIBACTERIA; SALMONELLA;

EID: 33847040290     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00478.x     Document Type: Review

References (157)

1. Goodman KJ, Correa P. The transmission of Helicobacter pylori. A critical review of the evidence. Int J Epidemiol 1995;24:875-87.
2. Torres J, Perez-Perez G, Goodman KJ, Atherton JC, Gold BD, Harris PR, la Garza AM, Guarner J, Munoz O. A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res 2000;31:431-69.
3. Scott DR, Marcus EA, Weeks DL, Sachs G. Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology 2002;123:187-95.
4. Smoot DT, Resau JH, Naab T, et al. Adherence of Helicobacter pylori to cultured human gastric epithelial cells. Infect Immun 1993;61:350-5.
5. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994;272:65-9.
6. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005;89:313-44.
7. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006;130:188-206.
8. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006;208:233-48.
9. The state of world health. In: The World Health Report 1996. Geneva: World Health Organisation, 1996:59-62.
10. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
11. Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol 2000;35 (Suppl. 12):90-7.
12. Macdonald JS, Steele G Jr, Gunderson LL. Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Philadelphia, PA: Lippincott, 1989:765-99.
13. Kabir S, Grant C, Daar AS. Serum levels of interleukin 1, interleukin 6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995;95:207-12.
14. Krogfelt KA, Lehours P, Megraud F. Diagnosis of Helicobacter pylori infection. Helicobacter 2005;10 (Suppl. 1):5-13.
15. Kabir S. Clinic-based testing for Helicobacter pylori infection by enzyme immunoassay of faeces, urine and saliva. Aliment Pharmacol Ther 2003;17:1345-54.
16. Kabir S. Detection of Helicobacter pylori in faeces by culture, PCR and enzyme immunoassay. J Med Microbiol 2001;50:1021-9.
17. Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of Helicobacter pylori infection. Dig Dis 2001;19:116-22.
18. Kabir S. The role of PCR in the diagnosis of Helicobacter pylori infections. Rev Med Microbiol 1999;10:197-212.
19. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
20. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001;19:523-63.
21. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9 (Suppl. 2):45-51.
22. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001;20:879-85.
23. Lu H, Yamaoka Y, Graham DY. Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 2005;21:653-9.
24. Ha NC, Oh ST, Sung JY, Cha KA, Lee MH, Oh BH. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol 2001;8:505-9.
25. Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun 1994;62:3604-7.
26. Mine T, Muraoka H, Saika T, Kobayashi I. Characteristics of a clinical isolate of urease-negative Helicobacter pylori and its ability to induce gastric ulcers in Mongolian gerbils. Helicobacter 2005;10:125-31.
27. Peek RM Jr, Miller GG, Tham KT, Perez-Perez GI, Zhao X, Atherton JC, Blaser MJ. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 1995;73:760-70.
28. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS, Rathbone BJ. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991;338:332-5.
29. Gebert B, Fischer W, Haas R. The Helicobacter pylori vacuolating cytotoxin: from cellular vacuolation to immunosuppressive activities. Rev Physiol Biochem Pharmacol 2004;152:205-20.
30. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000;191:467-76.
31. Ottemann KM, Lowenthal AC. Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infect Immun 2002;70:1984-90.
32. Leying H, Suerbaum S, Geis G, Haas R. Cloning and genetic characterization of a Helicobacter pylori flagellin gene. Mol Microbiol 1992;6:2863-74.
33. Suerbaum S, Josenhans C, Labigne A. Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. J Bacteriol 1993;175:3278-88.
34. Jones DM, Eldridge J, Fox AJ, Sethi P, Whorwell PJ. Antibody to the gastric Campylobacter-like organism ('Campylobacter pyloridis') - clinical correlations and distribution in the normal population. J Med Microbiol 1986;22:57-62.
35. Czinn SJ, Carr HS, Speck WT. Diagnosis of gastritis caused by Helicobacter pylori in children by means of an ELISA. Rev Infect Dis 1991;13 (Suppl. 8):700-3.
36. Yan J, Mao YF, Shao ZX. Frequencies of the expression of main protein antigens from Helicobacter pylori isolates and production of specific serum antibodies in infected patients. World J Gastroenterol 2005;11:421-5.
37. Bumann D, Jungblut PR, Meyer TF. Helicobacter pylori vaccine development based on combined subproteome analysis. Proteomics 2004;4:2843-8.
38. McAtee CP, Lim MY, Fung K, Velligan M, Fry K, Chow T, Berg DE. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin Diagn Lab Immunol 1998;5:537-42.
39. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47.
40. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999;397:176-80.
41. Jungblut PR, Bumann D, Haas G, Zimny-Arndt U, Holland P, Lamer S, Siejak F, Aebischer A, Meyer TF. Comparative proteome analysis of Helicobacter pylori. Mol Microbiol 2000;36:710-25.
42. Salama N, Guillemin K, McDaniel TK, Sherlock G, Tompkins L, Falkow S. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc Natl Acad Sci USA 2000;97:14,668-73.
43. Kimmel B, Bosserhoff A, Frank R, Gross R, Goebel W, Beier D. Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect Immun 2000;68:915-20.
44. Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y, Qureshi WA, Cadoz M, Monath TP. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004;53:1235-43.
45. Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, Osato M, Estes MK, Graham DY. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun 2005;73:2999-3006.
46. Aebischer T, Bumann D, Epple HJ, Graham DY, Metzger W, Schneider T, Stolte M, Zeitz M, Meyer TF. Development of a vaccine against Helicobacter pylori. Helicobacter 2005;10:547.
47. Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996;347:1630-1.
48. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:990-3.
49. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, Kelly CP, Monath TP, Michetti P. Safety and efficacy of low-dose Escherichia coli enterotoxin adjuvant for urease-based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002;51:634-40.
50. Sougioultzis S, Lee CK, Alsahli M, et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002;21:194-201.
51. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001;69:3581-90.
52. Losonsky GA, Kotloff KL, Walker RI. B-cell responses in gastric antrum and duodenum following oral-inactivated Helicobacter pylori whole-cell (HWC) vaccine and LT (R192G) in H. pylori-seronegative individuals. Vaccine 2003;2:562-5.
53. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999;18:449-59.
54. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000;68:2135-41.
55. Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, Haas G, Aebischer T, von Specht BU, Meyer TF. Safety and immunogenicity of live recombinant Salmonella enterica serovar typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001;20:845-52.
56. Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R, Bumann D, Aebischer T, Von Specht BU, Meyer TF. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004;22:2273-7.
57. Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect 2003;5:749-56.
58. Eaton KA. Animal models of Helicobacter gastritis. Curr Top Microbiol Immunol 1999;241:123-54.
59. Marchetti M, Arco B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995;267:1655-8.
60. Marchetti M, Rossi M, Giannelli V, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998;16:33-7.
61. Ghiara P, Rossi M, Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997;65:4996-5002.
62. Maeda K, Yamashiro T, Minoura T, Fujioka T, Nasu M, Nishizono A. Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole-cell sonicate in mice with chronic H. pylori infection. Microbiol Immunol 2002;46:613-20.
63. Ermak TH, Ding R, Ekstein B, Hill J, Myers GA, Lee CK, Pappo J, Kleanthous HK, Monath TP. Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria. Gastroenterology 1997;113:1118-28.
64. Goto T, Nishizono A, Fujioka T, Ikewaki J, Mifune K, Nasu M. Local secretory immunoglobulin A and post-immunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Infect Immun 1999;67:2531-9.
65. Sutton P, Danon SJ, Walker M, Thompson LJ, Wilson J, Kosaka T, Lee A. Post-immunisation gastritis and Helicobacter infection in the mouse: a long-term study. Gut 2001;49:467-73.
66. Aebischer T, Fischer A, Walduck A, Schlotelburg C, Lindig M, Schreiber S, Meyer TF, Bereswill S, Gobel UB. Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. FEMS Immunol Med Microbiol 2006;46:221-9.
67. Eisenberg JC, Czinn SJ, Garhart CA, et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun 2003;71:1820-7.
68. Minoura T, Kato S, Otsu S, Fujioka T, Iinuma K, Nishizono A. Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemic immunization using bacterial antigen-aluminium hydroxide. Clin Exp Immunol 2003;134:32-7.
69. Sutton P, O'Rourke J, Wilson J, Dixon MF, Lee A. Immunisation against Helicobacter felis infection protects against the development of gastric MALT lymphoma. Vaccine 2004;22:2541-6.
70. Nakagawa S, Osaki T, Fujioka Y, Yamaguchi H, Kamiya S. Long-term infection of Mongolian gerbils with Helicobacter pylori: microbiological, histopathological, and serological analyses. Clin Diagn Lab Immunol 2005;12:347-53.
71. Jeremy AHY, Dixon MF, Robinson PA, Crabtree JE. Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination. Microbes Infect 2006;8:340-6.
72. Rossi G, Ruggiero P, Peppoloni S, et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 2004;72:3252-9.
73. Smythies LE, Novak MJ, Waites KB, Lindsey JR, Morrow CD, Smith PD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 2005;23:901-9.
74. Hoffelner H, Haas R. Recombinant bacterial ghosts: versatile targeting vehicles and promising vaccine candidates. Int J Med Microbiol 2004;294:303-11.
75. Panthel K, Jechlinger W, Matis A, Rohde M, Szostak M, Lubitz W, Haas R. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003;71:109-16.
76. Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T, Ohara H, Yokoyama Y, Tochikubo K, Itoh M. Suppressive effects of DNA vaccines encoding heat-shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun 2000;277:159-63.
77. Miyashita M, Joh T, Watanabe K, et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori catalase. Vaccine 2002;20:2336-42.
78. Hatzifoti C, Bajaj-Elliott M, Dorrell N, Anyim M, Prentice MB, Nye KE, Wren B, Morrow WJ. A plasmid immunization construct encoding urease B of Helicobacter pylori induces an antigen-specific antibody response and upregulates the expression of beta-defensins and IL-10 in the stomachs of immunized mice. Vaccine 2004;22:2651-9.
79. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 2006;11:113-22.
80. Zavala-Spinetti L, Breslin MB, Correa H, Begue RE. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model. Helicobacter 2006;11:517-22.
81. Dzwonek A, Mikula M, Woszczynski M, Hennig E, Ostrowski J. Protective effect of vaccination with DNA of the H. pylori genomic library in experimentally infected mice. Cell Mol Biol Lett 2004;9:483-95.
82. Corthesy-Theulaz IE, Hopkins S, Bachmann D, et al. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 1998;66:581-6.
83. Gomez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998;16:460-71.
84. Rizos K, Lattemann CT, Bumann D, Meyer TF, Aebischer T. Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains. Infect Immun 2003;71:6320-8.
85. Xu C, Li ZS, Du YQ, Tu ZX, Gong YF, Jin J, Wu HY, Xu GM. Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA. World J Gastroenterol 2005;11:114-7.
86. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002;20:2431-8.
87. van Ginkel FW, Jackson RJ, Yoshino N, Hagiwara Y, Metzger DJ, Connell TD, Vu HL, Martin M, Fujihashi K, McGhee JR. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 2005;73:6892-902.
88. Lee CK, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H, Blanchard J, Monath TP. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 1999;17:3072-82.
89. Vajdy M, Singh M, Ugozzoli M, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003;110:86-94.
90. Guy B, Hessler C, Fourage S, Haensler J, Vialon-Lafay E, Rokbi B, Millet MJ. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998;16:850-6.
91. Pal SC, Deb BC, Sen Gupta PGSP, Sircar BK, Sen D, Sikdar SN. A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull World Health Organ 1980;58:741-5.
92. Kabir S. Cholera vaccines: the current status and problems. Rev Med Microbiol 2005;16:101-16.
93. Jiang W, Baker HJ, Smith BF. Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun 2003;71:40-6.
94. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 2006;24:1081-6.
95. Shi T, Liu WZ, Gao F, Shi GY, Xiao SD. Intranasal CpG- oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T-helper 1 type response and interferon-gamma correlate with the protection. Helicobacter 2005;10:71-9.
96. Sommer F, Wilken H, Faller G, Lohoff M. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 2004;72:1029-35.
97. Akhiani AA, Stensson A, Schon K, Lycke N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 2006;63:97-105.
98. Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995;172:161-72.
99. Czinn SJ, Nedrud JG. Oral immunization against Helicobacter pylori. Infect Immun 1991;59:2359-63.
100. Chen M, Lee A, Hazell S. Immunisation against gastric Helicobacter infection in a mouse/Helicobacter felis model. Lancet 1992;339:1120-1.
101. Chen M, Lee A, Hazell S, Hu P, Li Y. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Zentralbl Bakteriol 1993;280:155-65.
102. Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993;11:637-42.
103. Blanchard TG, Czinn SJ, Maurer R, Thomas WD, Soman G, Nedrud JG. Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun 1995;63:1394-9.
104. Ferrero RL, Thiberge JM, Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology 1997;113:185-94.
105. Keenan J, Oliaro J, Domigan N, Potter H, Aitken G, Allardyce R, Roake J. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun 2000;68:3337-43.
106. Keenan J, Neal S, Allardyce R, Roake J. Serum-derived IgG1-mediated immune exclusion as a mechanism of protection against H. pylori infection. Vaccine 2002;20:2981-8.
107. Thomas JE, Austin S, Dale A, McClean P, Harding M, Coward WA, Weaver LT. Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet 1993;342:121.
108. Thomas JE, Dale A, Bunn JE, Harding M, Coward WA, Cole TJ, Weaver LT. Early Helicobacter pylori colonisation: the association with growth faltering in The Gambia. Arch Dis Child 2004;89:1149-54.
109. Birkholz S, Schneider T, Knipp U, Stallmach A, Zeitz M. Decreased Helicobacter pylori-specific gastric secretory IgA antibodies in infected patients. Digestion 1998;59:638-45.
110. Berdoz J, Blanc CT, Reinhardt M, Kraehenbuhl JP, Corthesy B. In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci USA 1999;96:3029-34.
111. Weltzin R, Kleanthous H, Guirakhoo F, Monath TP, Lee CK. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997;15:370-6.
112. Akhiani AA, Schon K, Franzen LE, Pappo J, Lycke N. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004;172:5024-33.
113. Akhiani AA, Stensson A, Schon K, Lycke NY. IgA antibodies impair resistance against Helicobacter pylori infection: studies on immune evasion in IL-10-deficient mice. J Immunol 2005;174:8144-53.
114. Iizumi T, Yamanishi S, Kumagai Y, Nagata K, Kamiya S, Hirota K, Watanabe E, Sakamoto C, Takahashi H. Augmentation of Helicobacter pylori urease activity by its specific IgG antibody: implications for bacterial colonization enhancement. Biomed Res 2005;26:35-42.
115. D'Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT, Burroni D, Telford JL, Romagnani S, Del Prete G. T-helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997;158:962-7.
116. Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, Brooks EG, Graham DY, Reyes VE, Ernst PB. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T-helper cell 1 phenotype. Gastroenterology 1998;114:482-92.
117. Sommer F, Faller G, Konturek P, Kirchner T, Hahn EG, Zeus J, Rollinghoff M, Lohoff M. Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun 1998;66:5543-6.
118. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998;188:2277-88.
119. Pappo J, Torrey D, Castriotta L, Savinainen A, Kabok Z, Ibraghimov A. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun 1999;67:337-41.
120. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG. Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cell Immunol 1999;191:74-80.
121. Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000;78:28-30.
122. Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P. Gastric mucosal alpha (4) beta (7)-integrin-positive CD4 T lymphocytes and immune protection against Helicobacter infection in mice. Gastroenterology 2000;119:109-18.
123. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ. Murine CD4 T-cell response to Helicobacter infection. TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 1997;113:1848-57.
124. Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, Michetti P, Blum AL, Corthesy-Theulaz IE. Immunization of BALB/c mice with Helicobacter urease B induces a T-helper 2 response absent in Helicobacter infection. Gastroenterology 1998;115:891-7.
125. Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002;169:6977-84.
126. Sawai N, Kita M, Kodama T, Tanahashi T, Yamaoka Y, Tagawa Y, Iwakura Y, Imanishi J. Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 1999;67:279-85.
127. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin 12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 2003;71:910-21.
128. Day AS, Su B, Ceponis PJ, Jones NL, Yau E, Sieveking D, Sherman PM. Helicobacter pylori infection induces interleukin 18 production in gastric epithelial (AGS) cells. Dig Dis Sci 2004;49:1830-5.
129. Akhiani AA, Schon K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J Immunol 2004;173:3348-56.
130. Panthel K, Faller G, Haas R. . Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect Immun 2003;71:794-800.
131. Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin 4. Infect Immun 2003;71:3628-33.
132. Aebischer T, Laforsch S, Hurwitz R, Brombacher F, Meyer TF. Immunity against Helicobacter pylori: significance of interleukin 4 receptor alpha chain status and gender of infected mice. Infect Immun 2001;69:556-8.
133. Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis 2001;184:308-14.
134. Blanchard TG, Eisenberg JC, Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T-cell activation contributes to vaccine efficacy. Vaccine 2004;22:888-97.
135. Matsumoto Y, Blanchard TG, Drakes ML, Basu M, Redline RW, Levine AD, Czinn SJ. Eradication of Helicobacter pylori and resolution of gastritis in the gastric mucosa of IL-10-deficient mice. Helicobacter 2005;10:407-15.
136. Walduck A, Schmitt A, Lucas B, Aebischer T, Meyer TF. Transcription profiling analysis of the mechanisms of vaccine-induced protection against H. pylori. FASEB J 2004;18:1955-7.
137. Aebischer T, Schmitt A, Walduck AK, Meyer TF. Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol 2005;295:343-53.
138. Rahn W, Redline RW, Blanchard TG. Molecular analysis of Helicobacter pylori-associated gastric inflammation in naive versus previously immunized mice. Vaccine 2004;23:807-18.
139. Mueller A, O'Rourke J, Chu P, et al. Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc Natl Acad Sci USA 2003;100:12,289-94.
140. Velin D, Bachmann D, Bouzourene H, Michetti P. Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology 2005;129:142-55.
141. Boncristiano M, Paccani SR, Barone S, Ulivieri C, Patrussi L, Ilver D, Amedei A, D'Elios MM, Telford JL, Baldari CT. The Helicobacter pylori vacuolating toxin inhibits T-cell activation by two independent mechanisms. J Exp Med 2003;198:1887-97.
142. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T-lymphocyte activation. Science 2003;301:1099-102.
143. Shirasaka D, Aoyama N, Sakashita M, et al. Relationship between gastric ulcer and Helicobacter pylori VacA detected in gastric juice using bead-ELISA method. Helicobacter 2002;7:281-6.
144. Schmees C, Gerhard M, Treptau T, Voland P, Schwendy S, Rad R, Prinz C. VacA-associated inhibition of T-cell function: reviewed and reconsidered. Helicobacter 2006;11:144-6.
145. Sundrud MS, Torres VJ, Unutmaz D, Cover TL. Inhibition of primary human T-cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci USA 2004;101:7727-32.
146. Gerhard M, Schmees C, Voland P, et al. A secreted low-molecular-weight protein from Helicobacter pylori nduces cell-cycle arrest of T cells. Gastroenterology 2005;128:1327-39.
147. Zabaleta J, McGee DJ, Zea AH, Hernandez CP, Rodriguez PC, Sierra RA, Correa P, Ochoa AC. Helicobacter pylori arginase inhibits T-cell proliferation and reduces the expression of the TCR zeta-chain (CD3ζ). J Immunol 2004;173:586-93.
148. Goluszko P, Nowicki B. Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect Immun 2005;73:7791-6.
149. Hessey SJ, Spencer J, Wyatt JI, Sobala G, Rathbone BJ, Axon AT, Dixon MF. Bacterial adhesion and disease activity in Helicobacter-associated chronic gastritis. Gut 1990;31:134-8.
150. Ansorg R, Muller KD, von Recklinghausen G, Nalik HP. Cholesterol binding of Helicobacter pylori. Zentralbl Bakteriol 1992;276:323-9.
151. Trampenau C, Muller KD. Affinity of Helicobacter pylori to cholesterol and other steroids. Microbes Infect 2003;5:13-7.
152. Hirai Y, Haque M, Yoshida T, Yokota K, Yasuda T, Oguma K. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis. J Bacteriol 1995;177:5327-33.
153. Kawakubo M, Ito Y, Okimura Y, Kobayashi M, Sakura K, Kasama S, Fukuda MN, Fukuda M, Katsuyama T, Nakayama J. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004;305:1003-6.
154. Lee H, Kobayashi M, Wang P, Nakayama J, Seeberger PH, Fukuda M. Expression cloning of cholesterol alpha-glucosyltransferase, a unique enzyme that can be inhibited by natural antibiotic gastric mucin O-glycans, from Helicobacter pylori. Biochem Biophys Res Commun 2006;349:1235-41.
155. Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, Zahringer U, Mollenkopf HJ, Heinz E, Meyer TF. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat Med 2006;12:1030-8.
156. Velin D, Michetti P. Immunology of Helicobacter pylori infection. Digestion 2006;73:116-23.
157. Emancipator D, Nedrud JG, Czinn SJ. Helicobacter pylori vaccines: is DNA the answer? Helicobacter 2006;11:513-6.